Hemay005
Sponsors
Tianjin Hemay Bio-Tech Co., Ltd, Tianjin Hemay Pharmaceutical Co., Ltd, Ganzhou Hemay Pharmaceutical Co., Ltd
Conditions
Active Ankylosing SpondylitisBehçet DiseaseBehçet's DiseaseHemay005, Atopic DermatitisPsoriasis
Phase 1
Safety and Pharmacokinetics of Hemay005 In Healthy Male Subjects
CompletedNCT03007810
Start: 2016-12-31End: 2018-06-30Updated: 2018-06-19
Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects
NCT03570346
Start: 2018-07-10End: 2018-12-01Target: 24Updated: 2018-10-02
A Food Effect Study to Assess Pharmacokinetics of Hemay005 in Healthy Volunteers
NCT03577626
Start: 2018-10-10End: 2019-03-01Target: 12Updated: 2018-07-05
Multiple Ascending Dose Study to Assess Safety and Pharmacokinetics of Hemay005 In Healthy Subjects
CompletedNCT04837235
Start: 2021-04-29End: 2021-08-25Updated: 2024-03-06
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage
RecruitingNCT06376474
Start: 2024-04-28End: 2025-12-31Target: 24Updated: 2025-12-04
To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment
CompletedNCT06380153
Start: 2024-05-07End: 2025-04-16Updated: 2025-12-04
Bioequivalence Test of Hemay005 Tablets
CompletedNCT06610903
Start: 2024-09-15End: 2025-02-17Updated: 2025-03-18
Pharmacokinetic Interactions Between Hemay005 Tablets and Midazolam Maleate Tablets
CompletedNCT06610890
Start: 2024-12-12End: 2025-01-20Updated: 2025-12-03
Phase 2
A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease
TerminatedNCT04609397
Start: 2020-11-30End: 2022-04-30Updated: 2022-06-21
Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis
CompletedNCT05407246
Start: 2022-08-05End: 2023-08-18Updated: 2024-01-11
A Study of Hemay005 in Adult With Atopic Dermatitis
CompletedNCT05769946
Start: 2022-11-24End: 2024-02-21Updated: 2024-03-01